
Companies partner on TCR T-cell therapy for head & neck cancer
Adaptimmune Therapeutics and Galapagos have entered into a clinical collaboration agreement to develop Adaptimmune’s TCR T-cell therapy for head and neck cancer and other potential solid tumours. Under the terms of the agreement, Adaptimmune will receive an upfront exclusivity payment of $70 million, plus $15 million… Read More











